Smouldering systemic mastocytosis
MONDO:0015557Smouldering systemic mastocytosis is a type of systemic mastocytosis (SM). This clonal hematologic disease, with a slow progression, results in an accumulation of neoplastic mast cells in the visceral organs over time and patients present with splenomegaly, hypercellular marrow and, in some cases, urticaria pigmentosa-like skin lesions.
1856 clinical trials for this condition and its sub-types, 3 tagged with Smouldering systemic mastocytosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New pill aims to tame rare mast cell disease
Disease control Recruiting nowThis study tests an experimental drug called elenestinib (BLU-263) in people with indolent systemic mastocytosis, a rare condition where too many mast cells cause symptoms like flushing, itching, and stomach issues. About 534 participants will receive either the drug or a placebo…
Phase 2/3 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for mastocytosis patients: expanded access to bezuclastinib
Disease control Expanded accessThis program provides the investigational drug bezuclastinib to adults with systemic mastocytosis who have failed or cannot tolerate standard treatments. Participants must be at least 18 years old and able to swallow tablets. The goal is to offer a potential treatment option when…
Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC